Table 1. Contents and Changes in Revised Guideline.
| I. Preparation of Tests Using Contrast Agents | ||
| 1. Preparation of intravenous contrast injection | ||
| 2. Warming of contrast agent | ||
| 3. Fasting | ||
| 4. Instructions for use of contrast medium and obtaining patient consent | ||
| 5. Infection control when contrast medium is used | ||
| *Added content about auto-injector and connection line | ||
| II. Extravasation of Contrast Agent | ||
| 1. Risk factors for extravasation | ||
| 2. Measures to reduce extravasation | ||
| 3. Treatment of extravasation | ||
| III. Harmful Reaction of Iodinated Contrast Agent | ||
| 1. Acute adverse reactions to iodinated contrast agents | ||
| *Added information on skin tests during the test to identify high-risk groups | ||
| *Added information on replacing contrast medium during measures to prevent acute reactions | ||
| *Added information on the use of oral preparations and antihistamines as a pre-exam treatment | ||
| *Added instructions for treatment before ESUR test | ||
| 2. Delayed adverse reaction to iodized contrast agent | ||
| 3. Treatment and pretreatment of iodide contrast agent hypersensitivity reaction | ||
| 4. Kidney adverse reactions | ||
| *Correction and addition of definitions, mechanisms of development, diagnosis, risk factors, and systemic function measurement prior to examination | ||
| *Addition of information on avoidance and selection of contrast media for the prevention of nephrotoxicity, other therapies such as fluids, and use of contrast media in patients taking dialysis and metformin | ||
| 5. Other toxicity | ||
| IV. Harmful Reaction of Gadolinium Contrast Agent | ||
| 1. Harmful reaction by gadolinium contrast agent | ||
| 2. Treatment and pretreatment of gadolinium contrast agent hypersensitivity reaction | ||
| 3. Nephrogenic systemic fibrosis | ||
| 4. Kidney adverse reaction of gadolinium contrast agent | ||
| 5. Other adverse reactions | ||
| V. Use of Contrast Agents in Special Circumstances | ||
| 1. Pregnancy | ||
| 2. Lactation | ||
| 3. Children | ||
| 4. Drug Interactions | ||
| 5. Clinical Laboratory Interactions | ||
| VI. Appendix | ||
| 1. References | ||
| 2. Explanation and consent for the use of contrast medium | ||
| 3. Consent | ||
| 4. Checklist before the inspection | ||
| 5. Contrast Report | ||
Asterisk are newly added or corrected contents.